INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Xbryk (denosumab-dssb; SB16; 120 mg vial), a biosimilar…Original Article
FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva
